These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31912594)

  • 1. Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
    Petutschnigg J; Ferreira JP; Holzendorf V; Trippel TD; Hashemi D; Wachter R; Herrmann-Lingen C; Hasenfuß G; Zannad F; Pieske B; Edelmann F
    Eur J Heart Fail; 2020 Mar; 22(3):559-561. PubMed ID: 31912594
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).
    Edelmann F; Schmidt AG; Gelbrich G; Binder L; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
    Eur J Heart Fail; 2010 Aug; 12(8):874-82. PubMed ID: 20538867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
    Fernandes BP; Conceição LSR; Martins-Filho PRS; de Santana Motta DRM; Carvalho VO
    J Card Fail; 2018 Sep; 24(9):618-621. PubMed ID: 30194985
    [No Abstract]   [Full Text] [Related]  

  • 4. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.
    McDiarmid AK; Swoboda PP; Erhayiem B; Bounford KA; Bijsterveld P; Tyndall K; Fent GJ; Garg P; Dobson LE; Musa TA; Foley JRJ; Witte KK; Kearney MT; Greenwood JP; Plein S
    J Am Heart Assoc; 2020 Jan; 9(1):e011521. PubMed ID: 31852424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
    Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
    JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
    Onarecker C
    J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
    Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
    Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
    Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
    Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
    Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the H
    Myhre PL; Vaduganathan M; Claggett BL; Lam CSP; Desai AS; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Shah AM; Lewis EF; Rouleau J; Pitt B; Solomon SD
    Eur J Heart Fail; 2019 Oct; 21(10):1288-1291. PubMed ID: 31332920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone for heart failure with preserved ejection fraction.
    Morawietz H; Bornstein SR
    N Engl J Med; 2014 Jul; 371(2):181. PubMed ID: 25006730
    [No Abstract]   [Full Text] [Related]  

  • 16. Spironolactone for heart failure with preserved ejection fraction.
    Kumar N; Garg N
    N Engl J Med; 2014 Jul; 371(2):180. PubMed ID: 25006729
    [No Abstract]   [Full Text] [Related]  

  • 17. Spironolactone for heart failure with preserved ejection fraction.
    Efthimiadis GK; Zegkos T; Karvounis H
    N Engl J Med; 2014 Jul; 371(2):179-80. PubMed ID: 25006728
    [No Abstract]   [Full Text] [Related]  

  • 18. Spironolactone for heart failure with preserved ejection fraction.
    Dalzell JR
    N Engl J Med; 2014 Jul; 371(2):179. PubMed ID: 25006727
    [No Abstract]   [Full Text] [Related]  

  • 19. Spironolactone for heart failure with preserved ejection fraction.
    Pfeffer MA; Pitt B; McKinlay SM
    N Engl J Med; 2014 Jul; 371(2):181-2. PubMed ID: 25006726
    [No Abstract]   [Full Text] [Related]  

  • 20. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.